[Current position of the Professional Group of Dermatologic Oncology on high dosage therapy with interferon-alpha-2b].
Brockmeyer
N H
NH
Klinik für Dermatologie und Allergologie der Ruhr-Universität Bochum.
Hoffmann
K
K
Altmeyer
P
P
D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D016896:Treatment Outcome
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Aktuelle Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie zur Hochdosistherapie mit Interferon-alpha-2b.